Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
Qiong Yang,1–4,* Chenxi Yin,1,3,4,* Fangxin Liao,1,3,4 Yuanyuan Huang,1,3,4 Wenzhuo He,1,3,4 Chang Jiang,1,3,4 Guifang Guo,1,3,4 Bei Zhang,1,3,4 Liangping Xia1,3,41VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China; 2Department of O...
Main Authors: | Yang Q, Yin CX, Liao FX, Huang YY, He WZ, Jiang C, Guo GF, Zhang B, Xia LP |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-09-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/bevacizumab-plus-chemotherapy-as-third--or-later-line-therapy-in-patie-peer-reviewed-article-OTT |
Similar Items
-
Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
by: Yang Q, et al.
Published: (2018-05-01) -
Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
by: Yin CX, et al.
Published: (2014-08-01) -
Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
by: Geva R, et al.
Published: (2013-01-01) -
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
by: Lin Shui, et al.
Published: (2018-08-01) -
First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
by: Yu‐Wen Zhou, et al.
Published: (2021-05-01)